(AOF) – NFL Biosciences announces that some 3 million euros will be raised in the form of capital increases. The biotech developing botanical medicines for the treatment of dependencies and addictions specifies that the price will be 2.05 euros per new share, showing a discount of 20.23% compared to the closing price of April 11, 2024. aims to anticipate the implementation of the Phase 3 clinical study of NFL-101, its drug candidate for the indication of smoking cessation, and to advance the development of NFL-30.
This involves having an industrial organization capable of going from producing a few thousand doses of NFL 101 to millions. It will also involve advancing the development of NFL-301, its drug candidate for the indication of reducing alcohol consumption.
The company announces an offer reserved for professional investors and a public offer intended for individual investors via the PrimaryBid platform. The closing of the PrimaryBid offer will take place this April 11 at 10:00 p.m. and that of the offer reserved for professional investors on April 12 2024 before the markets open (subject to early closing).
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
